scholarly article | Q13442814 |
P50 | author | Ana Filipa Brito | Q114446544 |
José Guilherme Tralhão | Q114446545 | ||
Ana Margarida Abrantes | Q38589353 | ||
Maria Filomena Botelho | Q39051211 | ||
P2860 | cites work | Global cancer statistics | Q22241238 |
Mutation of p53 in recurrent hepatocellular carcinoma and its association with the expression of ZBP-89 | Q24685729 | ||
Liver-Directed Radiotherapy for Hepatocellular Carcinoma | Q26738869 | ||
New advances in hepatocellular carcinoma | Q26749329 | ||
Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region | Q26750444 | ||
Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoma | Q26773251 | ||
Systemic therapies for hepatocellular carcinoma | Q26775193 | ||
Targeting the insulin-like growth factor pathway in hepatocellular carcinoma | Q27006846 | ||
Hepatocellular carcinoma: epidemiology, biology, diagnosis, and therapies | Q27026025 | ||
Management of hepatocellular carcinoma: An update | Q27860530 | ||
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 | Q27860674 | ||
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling | Q28296761 | ||
Hepatocellular carcinoma: epidemiology and molecular carcinogenesis | Q28306363 | ||
Management of hepatocellular carcinoma | Q29616230 | ||
Epidemiology of viral hepatitis and hepatocellular carcinoma | Q29617918 | ||
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis | Q29619508 | ||
A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. | Q33368982 | ||
p53 and chemosensitivity. | Q33779334 | ||
Relationship between therapeutic efficacy of arterial infusion chemotherapy and expression of P-glycoprotein and p53 protein in advanced hepatocellular carcinoma | Q33788566 | ||
The role of p53-target genes in human cancer | Q33861549 | ||
Non-viral causes of hepatocellular carcinoma | Q34041381 | ||
Paracrine in vivo inhibitory effects of hepatitis B virus X protein (HBx) on liver cell proliferation: an alternative mechanism of HBx-related pathogenesis | Q34068117 | ||
Systemic chemotherapy of liver tumors | Q34110952 | ||
Molecular pathogenesis of human hepatocellular carcinoma. | Q34167480 | ||
Genetic and epigenetic events in human hepatocarcinogenesis | Q34250052 | ||
Prognostic prediction and treatment strategy in hepatocellular carcinoma. | Q34547469 | ||
Natural history of hepatocellular carcinoma and current treatment options | Q34587869 | ||
The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective | Q34625481 | ||
The prognostic molecular markers in hepatocellular carcinoma | Q34668320 | ||
Role of radiotherapy in the management of hepatocellular carcinoma: A systematic review | Q34966816 | ||
Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges | Q35501246 | ||
Hepatocellular carcinoma and chemotherapy: the role of p53. | Q39222765 | ||
Human augmenter of liver regeneration is important for hepatoma cell viability and resistance to radiation-induced oxidative stress | Q39823488 | ||
Effective angiostatic treatment in a murine metastatic and orthotopic hepatoma model | Q40417528 | ||
Dysregulation of apoptosis in hepatocellular carcinoma cells | Q43166036 | ||
Fluorine-18 Fluorodeoxyglucose Uptake in Hepatocellular Carcinoma: Correlation with Glucose Transporters and p53 Expression | Q43189620 | ||
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma | Q80112177 | ||
MDM2 gene amplification is correlated to tumor progression but not to the presence of SNP309 or TP53 mutational status in primary colorectal cancers | Q80806778 | ||
Intracellular signaling and hepatocellular carcinoma | Q35586439 | ||
Focus on hepatocellular carcinoma. | Q35721877 | ||
Environmental factors and risk for hepatocellular carcinoma | Q35929261 | ||
Modulation of apoptosis as a target for liver disease | Q36066290 | ||
Updated treatment approach to hepatocellular carcinoma. | Q36097844 | ||
Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice | Q36199751 | ||
Survival and apoptosis: a dysregulated balance in liver cancer | Q36740628 | ||
TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer | Q36777331 | ||
Targeted therapies for hepatocellular carcinoma. | Q36928888 | ||
Hepatocellular carcinoma: epidemiology and clinical aspects. | Q37025200 | ||
Hepatocellular carcinoma--epidemiological trends and risk factors | Q37527585 | ||
Systemic therapies in hepatocellular carcinoma | Q37527632 | ||
Hepatocellular carcinoma: A global view. | Q37589349 | ||
Approach to radiation therapy in hepatocellular carcinoma | Q37661759 | ||
Mechanisms of HBV-related hepatocarcinogenesis | Q37698774 | ||
Role of estrogen in hepatocellular carcinoma: is inflammation the key? | Q37710885 | ||
Systemic therapy for advanced hepatocellular carcinoma: past, present, and future | Q37734197 | ||
Future perspectives in hepatocellular carcinoma | Q37765050 | ||
Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC): Molecular mechanisms and novel paradigms | Q37776350 | ||
Advanced hepatocellular carcinoma. Review of targeted molecular drugs. | Q37837305 | ||
Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review). | Q37983026 | ||
Emerging targeted strategies in advanced hepatocellular carcinoma | Q38086183 | ||
Positron emission tomography diagnostic imaging in multidrug-resistant hepatocellular carcinoma: focus on 2-deoxy-2-(18F)Fluoro-D-Glucose | Q38213800 | ||
Understanding the tumor suppressor PTEN in chronic alcoholism and hepatocellular carcinoma | Q38271796 | ||
Fas and TRAIL 'death receptors' as initiators of inflammation: Implications for cancer | Q38345723 | ||
The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications | Q38400354 | ||
Sorafenib: 10 years after the first pivotal trial. | Q38544841 | ||
The rationale for targeting TGF-β in chronic liver diseases. | Q38715538 | ||
Influence of P53 on the radiotherapy response of hepatocellular carcinoma. | Q38822712 | ||
P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 2 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | hepatocellular carcinoma | Q1148337 |
P304 | page(s) | 302 | |
P577 | publication date | 2016-10-10 | |
P1433 | published in | Oncology reviews | Q26841967 |
P1476 | title | Targeting Hepatocellular Carcinoma: What did we Discover so Far? | |
P478 | volume | 10 |
Q91940339 | A novel inhibitor of MDM2 oncogene blocks metastasis of hepatocellular carcinoma and overcomes chemoresistance |
Q41549246 | A proteomics-based investigation on the anticancer activity of alisertib, an Aurora kinase A inhibitor, in hepatocellular carcinoma Hep3B cells |
Q45872155 | Efficacy of combining ING4 and TRAIL genes in cancer-targeting gene virotherapy strategy: First evidence in preclinical hepatocellular carcinoma |
Q40070928 | Extrahepatic metastasis of hepatocellular carcinoma to the paravertebral muscle: A case report. |
Q41413012 | High MRPS23 expression contributes to hepatocellular carcinoma proliferation and indicates poor survival outcomes |
Q64091327 | Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges |
Q91179083 | MERIT: Systematic Analysis and Characterization of Mutational Effect on RNA Interactome Topology |
Q59354957 | Mutations in and nucleotide excision repair genes are correlated with prognosis of hepatitis B virus-associated hepatocellular carcinoma |
Q58796653 | NFATc1 is a tumor suppressor in hepatocellular carcinoma and induces tumor cell apoptosis by activating the FasL-mediated extrinsic signaling pathway |
Q58579029 | Synergistic antitumor effect of a γ-secretase inhibitor PF-03084014 and sorafenib in hepatocellular carcinoma |
Q57119938 | Tsumura-Suzuki obese diabetic mice-derived hepatic tumors closely resemble human hepatocellular carcinomas in metabolism-related genes expression and bile acid accumulation |
Q41618935 | miRNA-346 promotes proliferation, migration and invasion in liver cancer |
Search more.